Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis

Prostate

Volumn 69, Issue 9, 2009, Pages 976-981

  Fleischmann, Achim ^a,b   Schlomm, Thorsten ^a   Köllermann, Jens ^a   Sekulic, Nikolina ^b   Huland, Hartwig ^a   Mirlacher, Martina ^a   Sauter, Guido ^a   Simon, Ronald ^a   Erbersdobler, Andreas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Immune system; Mast cells; Prognosis; Prostate cancer; Tissue microarray

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CELL DENSITY; DISEASE ASSOCIATION; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TISSUE MICROARRAY;

AGED; CELL COUNT; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MAST CELLS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-KIT; RISK FACTORS;

EID: 67049119139     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20948     Document Type: Article

References (30)

1. Alberti C. Prostate cancer progression and surrounding microenvironment. Int J Biol Markers 2006;21(2):88-95. (Pubitemid 44210037)
2. Metz M, Maurer M. Mast cells - Key effector cells in immune responses. Trends Immunol 2007;28(5):234-241. (Pubitemid 46654869)
3. Leslie M. Mast cells show their might. Science 2007;317(5838):614-616.
4. Theoharides TC, Conti P. Mast cells: The Jekyll and Hyde of tumor growth. Trends Immunol 2004;25(5):235-241. (Pubitemid 38501669)
5. Acikalin MF, Oner U, Topcu I, Yasar B, Kiper H, Colak E. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis 2005;37(3):162-169. (Pubitemid 41070534)
6. Chan JK, Magistris A, Loizzi V, Lin F, Rutgers J, Osann K, DiSaia PJ, Samoszuk M. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol 2005;99(1):20-25. (Pubitemid 41354578)
7. Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B, Bajdik C, Gelmon K, Chia S, Hayes M. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004;17(6):690-695. (Pubitemid 38715492)
8. Elpek GO, Gelen T, Aksoy NH, Erdogan A, Dertsiz L, Demircan A, Keles N. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol 2001;54(12):940-944. (Pubitemid 34032889)
9. Jiang YA, Zhang YY, Luo HS, Xing SF. Mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma. World J Gastroenterol 2002;8(6):1005-1008. (Pubitemid 35446410)
10. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999;189(4):487-495.
11. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: A study of 4,444 cases. Breast Cancer Res Treat 2008;107(2):249-257. (Pubitemid 350265695)
12. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000;88(12):2686-2692. (Pubitemid 30417928)
13. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005;23(35):8959-8967. (Pubitemid 46211481)
14. Aydin O, Dusmez D, Cinel L, Doruk E, Kanik A. Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia. Pathol Res Pract 2002;198(4):267-271. (Pubitemid 34495573)
15. Gupta RK. Mast cell variations in prostate and urinary bladder. Arch Pathol 1970;89(4):302-305.
16. Sari A, Serel TA, Candir O, Ozturk A, Kosar A. Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 1999;84(7):851-853. (Pubitemid 29500055)
17. Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, Tsujimura A, Nakayama M, Aozasa K, Okuyama A. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007;97(7):952-956. (Pubitemid 47519307)
18. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007;13(22 Pt 1):6579-6584. (Pubitemid 350206791)
19. Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, Henke RP. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: Differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002;41(1):40-46. (Pubitemid 34760124)
20. Zalatnai A. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr Mol Med 2006;6(6):685-693. (Pubitemid 44377767)
21. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30(12):1797-1803. (Pubitemid 24377155)
22. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: Association with cancer progression. Cancer Res 2000;60(20):5857-5861. (Pubitemid 30808324)
23. Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD. Protective immunosurveillance and therapeutic antitumor activity of {gamma}{delta} T cells demonstrated in a mouse model of prostate cancer. J Immunol 2008;180(9):6044- 6053.
24. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: Biology, therapeutics, and challenges. J Clin Oncol 2005;23(32):8262-8269.
25. Luiten RM, Fleuren GJ, Warnaar SO, Litvinov SV. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen. Lab Invest 1996;74(2):467-475. (Pubitemid 26072087)
26. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26(3):312-319. (Pubitemid 34184454)
27. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159(6):2249-2256. (Pubitemid 33104278)
28. Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194(3):349-357. (Pubitemid 32624562)
29. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006;118(9):2190-2194.
30. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M. Advances in specific immunotherapy for prostate cancer. Eur Urol 2008;53(4):694-708.